According to our (Global Info Research) latest study, the global AI Drug Repurposing Platform market size was valued at US$ 1338 million in 2025 and is forecast to a readjusted size of US$ 6336 million by 2032 with a CAGR of 23.9% during review period.
An AI drug repurposing platform is a computational analytics system for approved drugs, clinical-stage assets and shelved compounds. It integrates biomedical knowledge graphs, omics data, clinical trials, real-world data, literature and patent information, and uses machine learning, network medicine, causal inference and large language models to identify new drug-disease links, indication expansion opportunities, combination-therapy leads and translational evidence. It mainly serves pharmaceutical companies, biotechs, research institutes and foundations in pipeline reassessment, rare-disease development and asset rescue, with a blended gross margin of about 65%.
Demand is mainly driven by pharmaceutical cost reduction, redevelopment of existing assets under patent-cliff pressure, rare-disease and niche-indication development, and public-health response scenarios. Compared with de novo drug discovery, repurposing platforms re-rank drug-disease relationships on the basis of existing safety, pharmacokinetic and clinical experience, making them easier to move into proof-of-concept validation, indication expansion and out-licensing discussions.
The supply side is moving from simple literature mining or similarity search toward integrated knowledge graphs, multi-omics, real-world data, clinical-trial data and explainable models. Buyers evaluate not only algorithmic hit rates, but also data coverage, evidence traceability, private-data integration, API or private deployment, security compliance and wet-lab validation capability. Suppliers that combine platform software, expert services and experimental validation loops are better positioned for long-term partnerships.
Regional demand is led by large pharmaceutical companies, biotechs and research foundations in North America and Europe, while Asia-Pacific is benefiting from local innovative-drug pipelines and rising investment in AI-enabled pharma. Key risks include public-data bias, real-world-data compliance, verifiability of predictions and complex commercial rights around candidate drugs, but the return on investment remains attractive for customers with shelved assets, indication-expansion needs and rare-disease programs.
Report Scope
This report is a detailed and comprehensive analysis for global AI Drug Repurposing Platform market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global AI Drug Repurposing Platform market size and forecasts, in consumption value ($ Million), 2021-2032
Global AI Drug Repurposing Platform market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global AI Drug Repurposing Platform market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global AI Drug Repurposing Platform market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for AI Drug Repurposing Platform
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global AI Drug Repurposing Platform market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BenevolentAI, Healx, Insilico Medicine, Recursion, Lantern Pharma, SOM Biotech, Standigm, Pharos iBio, Aitia, Causaly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
AI Drug Repurposing Platform market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Target and Mechanism Mining
Drug–Disease Matching
Indication Expansion
Combination Therapy Prediction
Evidence Ranking and Validation
Safety and Translational Assessment
Market segment by Data Foundation
Biomedical Knowledge Graphs
Multi-Omics Data
Clinical and Real-World Data
Literature and Patent Data
Chemical and Target Interaction Data
Integrated Multimodal Data
Market segment by Algorithmic Method
Knowledge Graph Reasoning
Machine Learning Prediction
Network Medicine Analysis
Causal Inference Modeling
Generative and Language Models
Hybrid Expert-in-the-Loop Models
Market segment by Delivery Mode
SaaS Platform
Private Deployment
API and Data Service
Project-Based Collaboration
Platform with Wet-Lab Validation
Market segment by Application
Rare Disease Repurposing
Oncology Indication Expansion
Infectious Disease Response
CNS and Neurology Research
Immunology and Inflammation Research
Asset Rescue and Pipeline Optimization
Market segment by players, this report covers
BenevolentAI
Healx
Insilico Medicine
Recursion
Lantern Pharma
SOM Biotech
Standigm
Pharos iBio
Aitia
Causaly
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe AI Drug Repurposing Platform product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of AI Drug Repurposing Platform, with revenue, gross margin, and global market share of AI Drug Repurposing Platform from 2021 to 2026.
Chapter 3, the AI Drug Repurposing Platform competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and AI Drug Repurposing Platform market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of AI Drug Repurposing Platform.
Chapter 13, to describe AI Drug Repurposing Platform research findings and conclusion.
Summary:
Get latest Market Research Reports on AI Drug Repurposing Platform. Industry analysis & Market Report on AI Drug Repurposing Platform is a syndicated market report, published as Global AI Drug Repurposing Platform Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of AI Drug Repurposing Platform market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.